Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology

Infection and Immunity

Volumn 76, Issue 8, 2008, Pages 3577-3586

  Russo, Thomas A ^a,b   Beanan, Janet M ^a,b   Olson, Ruth ^a,b   MacDonald, Ulrike ^a,b   Luke, Nicole R ^a,b   Gill, Steven R ^a   Campagnari, Anthony A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; INTERLEUKIN 1BETA; MUCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; CYTOKINE; PROTEIN; VIRULENCE FACTOR;

ACINETOBACTER BAUMANNII; ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; DEATH; DISEASE COURSE; ESCHERICHIA COLI; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GENE DISRUPTION; GENE IDENTIFICATION; GENETIC SCREENING; HOST PATHOGEN INTERACTION; HYPOTHESIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NEUTROPENIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROVOCATION TEST; RAT; RESPIRATORY FAILURE; SOFT TISSUE INFECTION; ANIMAL; BACTERIAL COUNT; CHEMISTRY; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG; LUNG LAVAGE; MICROBIOLOGY; NEUTROPHIL; PATHOGENICITY; PATHOLOGY; SERUM BACTERICIDAL ACTIVITY; SKIN; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BLOOD BACTERICIDAL ACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; COLONY COUNT, MICROBIAL; CYTOKINES; DISEASE MODELS, ANIMAL; LUNG; MUTAGENESIS, INSERTIONAL; NEUTROPHILS; PNEUMONIA; PROTEINS; RATS; SKIN; SOFT TISSUE INFECTIONS; SURVIVAL ANALYSIS; VIRULENCE FACTORS;

EID: 48849111569     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00269-08     Document Type: Article

References (51)

1. Anstey, N. M., B. J. Currie, M. Hassell, D. Palmer, B. Dwyer, and H. Seifert. 2002. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J. Clin. Microbiol. 40:685-686.
2. Anstey, N. M., B. J. Currie, and K. M. Withnall. 1992. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin. Infect. Dis. 14:83-91.
3. Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.
4. Bernabeu-Wittel, M., C. Pichardo, A. Garcia-Curiel, M. E. Pachon-Ibanez, J. Ibanez-Martinez, M. E. Jimenez-Mejias, and J. Pachon. 2005. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. 11:319-325.
5. Centers for Disease Control and Prevention. 2004. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb. Mortal. Wkly. Rep. 53:1063-1066.
6. Chen, M. Z., P. R. Hsueh, L. N. Lee, C. J. Yu, P. C. Yang, and K. T. Luh. 2001. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 120:1072-1077.
7. Dalhoff, A., G. Frank, and G. Luckhaus. 1982. The granuloma pouch: an in vivo model for pharmacokinetic and chemotherapeutic investigations. I. Biochemical and histological characterization. Infection 10:354-360.
8. Dalhoff, A., G. Frank, and G. Luckhaus. 1983. The granuloma pouch: an in vivo model for pharmacokinetic and chemotherapeutic investigations. II. Microbiological characterization. Infection 11:41-46.
9. Davidson, B., P. Knight, J. Helinski, N. Nader, T. Shanley, and K. Johnson. 1999. The role of tumor necrosis factor-alpha in the pathogenesis of aspiration pneumonitis in rats. Anesthesiology 91:486-499.
10. Davis, K. A., K. A. Moran, C. K. McAllister, and P. J. Gray. 2005. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg. Infect. Dis. 11:1218-1224.
11. Department of Veterans Affairs. 2004. Update of the Colleagues' Letter sent April 23, 2004 concerning Acinetobacter baumannii. Department of Veterans Affairs, Veterans Health Administration, Washington, DC.
12. Ecker, J. A., C. Massire, T. A. Hall, R. Ranken, T. T. Pennella, C. A. Ivy, L. B. Blyn, S. A. Hofstadler, T. P. Endy, P. T. Scott, L. Lindler, T. Hamilton, C. Gaddy, K. Snow, M. Pe, J. Fishbain, D. Craft, G. Deye, S. Riddell, E. Milstrey, B. Petruccelli, S. Brisse, V. Harpin, A. Schink, D. J. Ecker, R. Sampath, and M. W. Eshoo. 2006. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J. Clin. Microbiol. 44:2921-2932.
13. Falagas, M. E., and E. A. Karveli. 2007. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin. Microbiol. Infect. 13:117-119.
14. Fournier, P. E., and H. Richer. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42:692-699.
15. Garzoni, C., S. Emonet, L. Legout, R. Benedict, P. Holfmeyer, L. Bernard, and J. Garbino. 2005. Atypical infections in tsunami survivors. Emerg. Infect. Dis. 11:1591-1593.
16. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
17. Jain, R., and L. H. Danziger. 2004. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother 38:1449-1459.
18. Johnson, E. N., T. C. Burns, R. A. Hayda, D. R. Hospenthal, and C. K. Murray. 2007. Infectious complications of open type III tibial fractures among combat casualties. Clin. Infect. Dis. 45:409-415.
19. Joly-Guillou, M. L. 2005. Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11:868-873.
20. Joly-Guillou, M. L., M. Wolff, R. Farinotti, A. Bryskier, and C. Carbon. 2000. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J. Antimicrob. Chemother. 46:827-830.
21. Joly-Guillou, M. L., M. Wolff, J. J. Pocidalo, F. Walker, and C. Carbon. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:345-351.
22. Knapp, S., C. W. Wieland, S. Florquin, R. Pantophlet, L. Dijkshoorn, N. Tshimbalanga, S. Akira, and T. van der Poll. 2006. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am. J. Respir. Crit. Care Med. 173:122-129.
23. Landman, D., J. M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravishankar, C. Flores, and S. Brooks. 2002. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, N.Y.: the preantibiotic era has returned. Arch. Intern. Med. 162:1515-1520.
24. Maegele, M., S. Gregor, E. Steinhausen, B. Bouillon, M. M. Heiss, W. Perbix, F. Wappler, D. Rixen, J. Geisen, B. Berger-Schreck, and R. Schwarz. 2005. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit. Care Med. 33:1136-1140.
25. Montero, A., J. Ariza, X. Cornelia, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54:1085-1091.
26. Pachon-Ibanez, M. E., F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual. 2006. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J. Antimicrob. Chemother. 58:689-692.
27. Pantopoulou, A., E. J. Giamarellos-Bourboulis, M. Raftogannis, T. Tsaganos, I. Dontas, P. Koutoukas, F. Baziaka, H. Giamarellou, and D. Perrea. 2007. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int. J. Antimicrob. Agents 29:51-55.
28. Paterson, D. L., and Y. Doi. 2007. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin. Infect. Dis. 45:1179-1181.
29. Perez, F., A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
30. Petersen, K., M. S. Riddle, J. R. Danko, D. L. Blazes, R. Hayden, S. A. Tasker, and J. R. Dunne. 2007. Trauma-related infections in battlefield casualties from Iraq. Ann. Surg. 245:803-811.
31. Renckens, R., J. J. Roelofs, S. Knapp, A. F. de Vos, S. Florquin, and T. van der Poll. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J. Infect. Dis. 193:187-195.
32. Rice, L. B. 2006. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 43:S100-S105.
33. Richet, H., and P. E. Fournier. 2006. Nosocomial infections caused by Acin etobacter baumannii: a major threat worldwide. Infect. Control Hosp. Epidemiol. 27:645-646.
34. Rodriguez-Hernandez, M. J., L. Cuberos, C. Pichardo, F. J. Caballero, I. Moreno, M. E. Jimenez-Mejias, A. Garcia-Curiel, and J. Pachon. 2001. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J. Antimicrob. Chemother. 47:479-482.
35. Rodriguez-Hernandez, M. J., M. E. Jimenez-Mejias, C. Pichardo, L. Cuberos, A. Garcia-Curiel, and J. Pachon. 2004. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin. Microbiol. Infect. 10:581-584.
36. Rodriguez-Hernandez, M. J., J. Pachon, C. Pichardo, L. Cuberos, J. Ibanez-Martinez, A. Garcia-Curiel, F. J. Caballero, I. Moreno, and M. E. Jimenez-Mejias. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45:493-501.
37. Russo, T., Y. Liang, and A. Cross. 1994. The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo. J. Infect. Dis. 169:112-118.
38. Russo, T., G. Sharma, C. Brown, and A. Campagnari. 1995. The loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo. Infect. Immun. 63:1263-1269.
39. Russo, T. A., L. A. Bartholomew, B. A. Davidson, J. D. Helinski, U. B. Carlino, P. R. Knight III, M. F. Beers, E. N. Atochina, R. H. Notter, and B. A. Holm. 2002. Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 283:L655-L663.
40. Russo, T. A., B. A. Davidson, J. M. Beanan, R. Olson, B. A. Holm, R. H. Notter, and P. R. Knight III. 2007. Capsule and O-antigen from an extraintestinal isolate of Escherichia coli modulate cytokine levels in rat macrophages in vitro and in a rat model of pneumonia. Exp. Lung Res. 33:337-356.
41. Russo, T. A., B. A. Davidson, U. B. Carlino-MacDonald, J. D. Helinski, R. L. Priore, and P. R. Knight III. 2003. The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia. FEMS Microbiol. Lett. 226:355-361.
42. Russo, T. A., B. A. Davidson, S. A. Genagon, N. M. Warholic, U. Macdonald, P. D. Pawlicki, J. M. Beanan, R. Olson, B. A. Holm, and P. R. Knight III. 2005. E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L207-L216.
43. Russo, T. A., M. C. Moffitt, C. H. Hammer, and M. M. Frank. 1993. TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity. Infect. Immun. 61:3578-3582.
44. Scott, P., G. Deye, A. Srinivasan, C. Murray, K. Moran, E. Hulten, J. Fishbain, D. Craft, S. Riddell, L. Lindler, J. Mancuso, E. Milstrey, C. T. Bautista, J. Patel, A. Ewell, T. Hamilton, C. Gaddy, M. Tenney, G. Christopher, K. Petersen, T. Endy, and B. Petruccelli. 2007. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin. Infect. Dis. 44:1577-1584.
45. Sunenshine, R. H., M. O. Wright, L. L. Maragakis, A. D. Harris, X. Song, J. Hebden, S. E. Cosgrove, A. Anderson, J. Carnell, D. B. Jernigan, D. G. Kleinbaum, T. M. Perl, H. C. Standiford, and A. Srinivasan. 2007. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis. 13:97-103.
46. Talbot, G. H., J. Bradley, J. E. Edwards, Jr., D. Gilbert, M. Scheid, and J. G. Bartlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
47. Tognim, M. C., S. S. Andrade, S. Silbert, A. C. Gales, R. N. Jones, and H. S. Sader. 2004. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int. J. Infect. Dis. 8:284-291.
48. Tong, M. J. 1972. Septic complications of war wounds. JAMA 219:1044-1047.
49. van Dessel, H., T. E. Kamp-Hopmans, A. C. Fluit, S. Brisse, A. M. de Smet, L. Dijkshoorn, A. Troelstra, J. Verhoef, and E. M. Mascini. 2002. Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurosurgical intensive care unit. J. Hosp. Infect. 51:89-95.
50. Van Looveren, M., and H. Goossens. 2004. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect. 10:684-704.
51. Villegas, M. V., and A. I. Hartstein. 2003. Acinetobacter outbreaks, 1977-2000. Infect. Control Hosp. Epidemiol. 24:284-295.